作者
Pantelis A Sarafidis, Panagiotis C Stafylas, Panagiotis I Georgianos, Athanasios N Saratzis, Anastasios N Lasaridis
发表日期
2010/5/1
来源
American Journal of Kidney Diseases
卷号
55
期号
5
页码范围
835-847
出版商
WB Saunders
简介
BACKGROUND
Because of the major clinical and economic burden of diabetic nephropathy, new therapeutic tools to delay its progression are needed. Recent studies suggest that thiazolidinediones have renal benefits. We aimed to evaluate the effect of thiazolidinediones on urinary albumin and protein excretion in patients with diabetes mellitus.
STUDY DESIGN
Systematic review and meta-analysis by searching MEDLINE/PubMed, EMBASE, and Cochrane CENTRAL databases (1991 to September 2009).
SETTING & POPULATION
Patients with diabetes mellitus.
SELECTION CRITERIA FOR STUDIES
Randomized controlled trials.
INTERVENTION
Thiazolidinediones (rosiglitazone and pioglitazone) compared with placebo or other antidiabetic agents.
OUTCOMES
Weighted (WMDs) and standardized mean differences (SMDs) for changes in urine albumin or protein excretion between the thiazolidinedione and …
引用总数
学术搜索中的文章
PA Sarafidis, PC Stafylas, PI Georgianos, AN Saratzis… - American Journal of Kidney Diseases, 2010